Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

142.83USD
19 Sep 2017
Change (% chg)

$-0.81 (-0.56%)
Prev Close
$143.64
Open
$143.90
Day's High
$144.12
Day's Low
$141.84
Volume
454,952
Avg. Vol
844,437
52-wk High
$149.17
52-wk Low
$96.18

Latest Key Developments (Source: Significant Developments)

BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris
Wednesday, 13 Sep 2017 06:00pm EDT 

Adds company name in headline:Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis.Says safety profile of Soliris was consistent with that observed in REGAIN study.Says ‍study is ongoing and planned to continue until January 2019​.Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales.Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study.  Full Article

Interim analysis from phase 3 open-label extension study of Soliris
Wednesday, 13 Sep 2017 06:00pm EDT 

Sept 13 (Reuters) - Alexion Pharmaceuticals Inc ::Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis.Says safety profile of Soliris was consistent with that observed in REGAIN study.Says ‍study is ongoing and planned to continue until January 2019​.Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales.Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study.  Full Article

Alexion to reduce 20 pct of its global workforce
Tuesday, 12 Sep 2017 08:00am EDT 

Sept 12 (Reuters) - Alexion Pharmaceuticals Inc :Alexion announces restructuring to advance corporate strategy.Alexion Pharmaceuticals Inc - ‍global workforce reduction of approximately 20 percent​.Alexion Pharmaceuticals Inc - ‍expect to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019​.Alexion Pharmaceuticals Inc - ‍expect to reinvest approximately $100 million annually to build pipeline.Alexion Pharmaceuticals - ‍ Alexion anticipates total pre-tax restructuring, related expenses associated with restructuring to be $340 million to $440 million​.Alexion Pharmaceuticals Inc - plans to relocate its headquarters to Boston, MA by mid-2018.Alexion - ‍expects that increased financial flexibility will allow co to reinvest approximately $100 million a year into research and development starting in 2018​.Alexion Pharmaceuticals Inc - ‍company's 2017 revenue guidance remains unchanged​.Alexion Pharmaceuticals Inc - company plans to have approximately 400 positions in Boston.Alexion Pharmaceuticals Inc - ‍pre-tax restructuring and related expenses of approximately $240 million to $300 million are expected to be recorded in 2017​.Alexion Pharmaceuticals Inc - ‍2017 GAAP EPS guidance will be impacted by restructuring and related expenses, 2017 non-GAAP EPS guidance is unchanged​.Alexion Pharmaceuticals Inc - ‍is right-sizing certain G&A functions, such as human resources, finance and information technology (IT).  Full Article

European Commission grants new indication for Soliris
Monday, 21 Aug 2017 09:25am EDT 

Aug 21 (Reuters) - Alexion Pharmaceuticals Inc ::European Commission grants new indication for Soliris® (Eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG).EC based approval of extended indication for Soliris on comprehensive clinical data from phase 3 regain study (MG-301).EC approved extension of indication for Soliris(Eculizumab) to include treatment of refractory generalized myasthenia gravis.  Full Article

Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027
Tuesday, 15 Aug 2017 04:05pm EDT 

Aug 15 (Reuters) - Alexion Pharmaceuticals Inc :Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027.Alexion Pharmaceuticals Inc - ‍Alexion is pursuing corresponding patent applications in other regions and countries, including Europe and Japan​.  Full Article

Blueprint Medicines to evaluate advance disease discovery program opportunities
Thursday, 27 Jul 2017 06:35am EDT 

July 27 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion.Says received written notice from Alexion of its decision to discontinue collaboration.Says believe existing cash, cash equivalents, excluding some items, to be sufficient to fund expenditure requirements into 2H 2019.  Full Article

Alexion receives positive CHMP opinion for Soliris in the EU
Friday, 23 Jun 2017 08:00am EDT 

June 23 (Reuters) - Alexion Pharmaceuticals Inc :Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union.Alexion Pharmaceuticals Inc says final decision from European Commission (EC) is anticipated in Q3 of 2017.  Full Article

Alexion Pharmaceuticals in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million
Tuesday, 13 Jun 2017 05:24pm EDT 

June 13 (Reuters) - Alexion Pharmaceuticals Inc ::Alexion Pharmaceuticals Inc - in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million .Alexion-Clancy will also receive restricted stock units valued at about $5.8 million,performance share units valued at target at about $3 million.  Full Article

Alexion Pharmaceuticals names Paul Clancy as CFO
Tuesday, 13 Jun 2017 04:30pm EDT 

June 13 (Reuters) - Alexion Pharmaceuticals Inc :Alexion names Paul Clancy chief financial officer.Alexion Pharmaceuticals Inc - Clancy will succeed Dave Anderson, who will continue to serve as CFO until july 31, 2017.For past 16 years, Clancy has been employed by Biogen where he has served as CFO for last ten years.Alexion Pharmaceuticals Inc - Clancy most recently served as executive vice president, finance and CFO and a member of executive committee of Biogen.  Full Article

Alexion Pharmaceuticals says CFO will resign
Tuesday, 23 May 2017 08:00am EDT 

May 23 (Reuters) - Alexion Pharmaceuticals Inc ::Alexion Pharmaceuticals Inc says Dave Anderson, chief financial officer, will resign his position at end of August.Alexion Pharmaceuticals Inc says a search for a new CFO is underway with SpencerStuart.  Full Article

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis